These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1527926)

  • 1. [Significance of complex hemodynamic studies for the choice of therapy with the beta-adrenergic blocker, atenolol, and the calcium antagonist, procorum, in patients with ischemic heart disease].
    Ulianova KN; Surovov IuA; Sedov VP; Sidorenko BA
    Kardiologiia; 1992 Feb; 32(2):112. PubMed ID: 1527926
    [No Abstract]   [Full Text] [Related]  

  • 2. Microperfusion in coronary artery disease under treatment with the calcium antagonist gallopamil.
    Eichstädt H; Danne O; Gutmann M; Langer M; Felix R; Schmutzler H
    Arzneimittelforschung; 1988 May; 38(5):700-3. PubMed ID: 3415712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and hemodynamic effects of long-term administration of gallopamil in patients with coronary artery disease and normal or impaired left ventricular function.
    Tartagni F; Maiello L; Marchetti G; Dondi M; Franchi R; Monetti N; Magnani B
    Am J Cardiol; 1989 Feb; 63(5):291-5. PubMed ID: 2913730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle].
    Chieppa S; Lobascio C; Brandini V; Iarussi D; Giuliani F; Langella S; De Simone R
    Cardiologia; 1989 Aug; 34(8):695-9. PubMed ID: 2605580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of calcium antagonists and beta receptor blockers on coronary vessel diameter].
    Rafflenbeul W; Jost S; Berger C; Lichtlen P
    Z Kardiol; 1989; 78 Suppl 5():16-9. PubMed ID: 2631476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Profile of the hemodynamic effect of gallopamil at rest and during exercise by angiocardio-scintigraphic studies: preliminary data].
    Tartagni F; Marchetti G; Maiello L; Dondi M; Franchi R; Magnani B
    Cardiologia; 1987 Nov; 32(11):1249-53. PubMed ID: 3447697
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anti-ischemia effects of gallopamil and esmolol in an intra-individual comparison in patients with coronary heart disease].
    Mitrovic V; Oehm E; Minge C; Thürmann P; Schlepper M
    Z Kardiol; 1994 Jun; 83(6):431-8. PubMed ID: 7915067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Procorum].
    Wien Klin Wochenschr; 1988 Aug; 100(15):524-9. PubMed ID: 3051682
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacological effects on left diastolic ventricular function in acute myocardial infarct: comparison of gallopamil and atenolol].
    Natale E; Ricci R; Tubaro M; Milazzotto F
    G Ital Cardiol; 1991 Dec; 21(12):1295-303. PubMed ID: 1818002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-of-day variation in cardiovascular response to maximal exercise testing in coronary heart disease patients taking a beta-blocker.
    Dufour Doiron M; Prud'homme D; Boulay P
    Appl Physiol Nutr Metab; 2007 Aug; 32(4):664-9. PubMed ID: 17622280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Coraxan and atenolol: similarities and differences in correction of clinical and functional indices in therapy of patients with coronary heart disease].
    Tatarchenko IP; Pozdniakova NV; Kapelovich VIu; Biriuchenko MV
    Klin Med (Mosk); 2008; 86(3):47-51. PubMed ID: 18441705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of atenolol on the exercise symptoms of coronary patients. A double blind study (author's transl)].
    Bischoff K
    MMW Munch Med Wochenschr; 1981 Sep; 123(36):1337-40. PubMed ID: 6792528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease.
    Silke B; Verma SP; Sharma SK; Frais MA; Reynolds G; Taylor SH
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):155-61. PubMed ID: 2468927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regression of left heart hypertrophy in hypertensive patients as a result of antihypertensive therapy].
    Franz IW; Tönnesmann U; Behr U; Ketelhut R
    Z Kardiol; 1989; 78 Suppl 5():43-8. PubMed ID: 2561036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional analysis of infarct size reduction after administration of gallopamil in dogs.
    Faria DB; Goncalves FR; Maroko PR
    Arzneimittelforschung; 1990 Jan; 40(1):19-23. PubMed ID: 2339995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multicenter long-term study of gallopamil in patients with coronary heart disease].
    Sućić M; Schiemann J
    Arzneimittelforschung; 1984; 34(11):1587-94. PubMed ID: 6543136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study.
    Reyes E; Stirrup J; Roughton M; D'Souza S; Underwood SR; Anagnostopoulos C
    J Nucl Med; 2010 Jul; 51(7):1036-43. PubMed ID: 20554740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of ischemic heart disease in the elderly. Comparison of diltiazem, verapamil and gallopamil].
    Simonelli P; Papa A; Macciocchi B; Auriemma F; Vetrano A; Scaletta Romeo di Santillo M; Ceriello A
    Minerva Cardioangiol; 1993 May; 41(5):193-204. PubMed ID: 8355859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise-induced symptomatic and asymptomatic myocardial ischemia in patients with severe coronary artery disease: focus on the efficacy and safety of gallopamil.
    Zehender M; Kosscheck U; Hohnloser S; Weiss C; Meinertz T; Just H
    J Cardiovasc Pharmacol; 1992; 20 Suppl 7():S57-63. PubMed ID: 1284158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracoronary gallopamil during percutaneous transluminal coronary angioplasty.
    Rauch B; Richardt G; Barth R; Zimmermann R; Tillmanns H; Schömig A; Kübler W; Neumann FJ
    J Cardiovasc Pharmacol; 1992; 20 Suppl 7():S32-9. PubMed ID: 1284155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.